文献速递急性肾损伤肾小球疾病肾血管病与高血压

VEGF信号通路的治疗性抑制及其相关肾毒性

Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.
PubMed 文献 · J Am Soc Nephrol · 2019-01-14

本文综述VEGFA/VEGFR2信号抑制相关肾毒性的实验与临床证据,并探讨MAPK/ERK1/2、eNOS及mTOR等下游通路的作用。直接VEGFA抑制与肾特异性TMA相关,VEGFR酪氨酸激酶抑制多与微小病变和FSGS等肾小球病相关,RAF/MAPK/ERK抑制主要与肾小管间质损伤相关,mTOR抑制最常见白蛋白尿和足细胞损伤但也与肾特异性TMA相关。

要点

  • 直接VEGFA抑制(抗体或VEGF trap)与肾特异性TMA相关
  • VEGFR酪氨酸激酶抑制多与微小病变和FSGS等肾小球病相关
  • mTOR抑制最常见白蛋白尿和足细胞损伤,也可与肾特异性TMA相关

核心结论

  • VEGFA-VEGFR2抑制剂通过不同下游通路介导多种肾毒性,临床表现多样。

研究设计与样本

  • 综述,汇总VEGFA/VEGFR2信号抑制相关肾毒性的实验与临床证据。

主要发现

  • 直接VEGFA抑制通过抗体结合或VEGF trap与肾特异性TMA相关。
  • VEGFR酪氨酸激酶抑制优先与微小病变和FSGS等肾小球病相关。
  • RAF/MAPK/ERK下游通路抑制主要与肾小管间质损伤相关。
  • mTOR抑制最常见与白蛋白尿和足细胞损伤相关,但也与肾特异性TMA相关。

临床怎么用

  • 使用VEGFA/VEGFR2抑制剂时需监测肾特异性TMA、肾小球病和肾小管间质损伤。
  • 使用mTOR抑制剂时需关注白蛋白尿和足细胞损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inhibition of vascular endothelial growth factor A (VEGFA)/vascular endothelial growth factor receptor 2 (VEGFR2) signaling is a common therapeutic strategy in oncology, with new drugs continuously in development. In this review, we consider the experimental and clinical evidence behind the diverse nephrotoxicities associated with the inhibition of this pathway. We also review the renal effects of VEGF inhibition's mediation of key downstream signaling pathways, specifically MAPK/ERK1/2, endothelial nitric oxide synthase, and mammalian target of rapamycin (mTOR). Direct VEGFA inhibition via antibody binding or VEGF trap (a soluble decoy receptor) is associated with renal-specific thrombotic microangiopathy (TMA). Reports also indicate that tyrosine kinase inhibition of the VEGF receptors is preferentially associated with glomerulopathies such as minimal change disease and FSGS. Inhibition of the downstream pathway RAF/MAPK/ERK has largely been associated with tubulointerstitial injury. Inhibition of mTOR is most commonly associated with albuminuria and podocyte injury, but has also been linked to renal-specific TMA. In all, we review the experimentally validated mechanisms by which VEGFA-VEGFR2 inhibitors contribute to nephrotoxicity, as well as the wide range of clinical manifestations that have been reported with their use. We also highlight potential avenues for future research to elucidate mechanisms for minimizing nephrotoxicity while maintaining therapeutic efficacy.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Estrada CC, Maldonado A, Mallipattu SK, et al. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. J Am Soc Nephrol. 2019. PMID: 30642877. doi:10.1681/ASN.2018080853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。